These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Pharmacoeconomics. Ahuja J; Gupta M; Gupta AK; Kohli K Natl Med J India; 2004; 17(2):80-3. PubMed ID: 15141600 [TBL] [Abstract][Full Text] [Related]
5. Drug therapy: safety, effectiveness, and economics. Brandys J Przegl Lek; 2001; 58(4):226-8. PubMed ID: 11450340 [TBL] [Abstract][Full Text] [Related]
6. The future of pharmacoeconomics: a commentary. Langley PC Clin Ther; 1997; 19(4):762-9; discussion 760-1. PubMed ID: 9377619 [TBL] [Abstract][Full Text] [Related]
7. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Role of economic models in randomized clinical trials. Hlatky MA Am Heart J; 1999 May; 137(5):S41-6. PubMed ID: 10220595 [No Abstract] [Full Text] [Related]
8. Economic assessment within the clinical development program. Schulman KA; Llana T; Yabroff KR Med Care; 1996 Dec; 34(12 Suppl):DS89-95. PubMed ID: 8969317 [No Abstract] [Full Text] [Related]
9. Transparency in economic evaluations. Hill S Pharmacoeconomics; 2005; 23(10):967-9. PubMed ID: 16235971 [No Abstract] [Full Text] [Related]
10. Pharmacoeconomics: an emerging discipline. Letizia C Qual Assur; 1995 Mar; 4(1):68-74. PubMed ID: 8520866 [TBL] [Abstract][Full Text] [Related]
11. Synthesizing evidence from multiple studies. The role of meta-analysis in pharmacoeconomics. Lafata JE; Koch GG; Ward RE Med Care; 1996 Dec; 34(12 Suppl):DS136-45. PubMed ID: 8969322 [No Abstract] [Full Text] [Related]
12. Pharmacoeconomics comes of age? Walley T; Breckenridge A Clin Pharmacol Ther; 2008 Aug; 84(2):279-80. PubMed ID: 18563057 [TBL] [Abstract][Full Text] [Related]
13. Economic evaluation of pharmaceuticals. Frankenstein's monster or vampire of trials? O'Brien B Med Care; 1996 Dec; 34(12 Suppl):DS99-108. PubMed ID: 8969318 [No Abstract] [Full Text] [Related]
14. Accumulating evidence for the case of differential discounting. Postma MJ; Parouty M; Westra TA Expert Rev Clin Pharmacol; 2013 Jan; 6(1):1-3. PubMed ID: 23272787 [No Abstract] [Full Text] [Related]
15. Transparency of economic evaluations of health technologies. Rovira J Pharmacoeconomics; 2008; 26(3):181-3. PubMed ID: 18282013 [No Abstract] [Full Text] [Related]
16. Applied pharmacoeconomics: considerations to drive the choice of a prophylactic antithrombotic regimen. Iorio A J Thromb Haemost; 2003 May; 1(5):881-3. PubMed ID: 12871350 [No Abstract] [Full Text] [Related]